Key findings in HHT patients include the identification of somatic mutations in AVMs that lead to bi-allelic LOF in ACVRL1 or ENG15, and the observation that the anti-VEGFA antibody bevacizumab has possible therapeutic value in HHT 16,17. This evidence concerns the gene VEGFA and hereditary hemorrhagic telangiectasia.